Literature DB >> 6134818

Calcium-induced release from platelet membranes of fatty acids that modulate soluble guanylate cyclase.

R Gerzer, P Hamet, A H Ross, J A Lawson, J G Hardman.   

Abstract

Incubation of rat or rabbit platelet membranes with Ca++ induced the release of modulators of soluble guanylate cyclase. These modulators increased basal activity and inhibited sodium nitroprusside-stimulated activity in the absence or presence of dithiothreitol. The release, but not the effects, of the modulators was inhibited by trifluoperazine and by mepacrine. Indomethacin and oxyphenbutazone did not influence the release or effects of the modulators. The factors were identified as arachidonic and linoleic acids. These fatty acids produced comparable effects on crude soluble guanylate cyclase from platelets and on the homogeneously purified enzyme from bovine lung. In the presence of MgCl2, the maximal increase in basal activity was observed at 10 to 30 microM arachidonic or linoleic acid with the crude enzyme and at 3 to 6 microM with the purified enzyme. Inhibition of basal activity was observed at higher concentrations. Half-maximal inhibition of Mg++-supported, sodium nitroprusside-augmented activity was observed at 3 to 10 microM fatty acid. The effects of arachidonic acid occurred without a lag period and were quickly reversible. These data demonstrate that unsaturated fatty acids can be released from platelet membranes by a Ca++-dependent process in amounts that are high enough to alter soluble guanylate cyclase activity. The data also indicate that unsaturated fatty acids exert their effects on soluble guanylate cyclase without having to be converted to peroxides by other enzymes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134818

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Particulate guanylate cyclase and adenylate cyclase activities after activation with various agents in rabbit platelets. An ultracytochemical study.

Authors:  A Spreca; M G Rambotti; R Donato
Journal:  Histochem J       Date:  1991-03

Review 2.  The role of phosphoinositides in signal transduction.

Authors:  M C Sekar; L E Hokin
Journal:  J Membr Biol       Date:  1986       Impact factor: 1.843

3.  Simultaneous measurement of endothelium-derived relaxing factor by bioassay and guanylate cyclase stimulation.

Authors:  K Kondo; J A Mitchell; G de Nucci; J R Vane
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

4.  Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats.

Authors:  L Rothermund; A Friebe; M Paul; D Koesling; R Kreutz
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  Atrial natriuretic peptide involvement in human platelet aggregability in vitro.

Authors:  R Pella; A von Ruecker; F Bidlingmaier
Journal:  Klin Wochenschr       Date:  1988-01-15

6.  [The heart as an endocrine organ: the discovery of a new hormone].

Authors:  R Gerzer
Journal:  Klin Wochenschr       Date:  1985-06-18

7.  Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta.

Authors:  S M Yu; S C Kuo
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

8.  Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells.

Authors:  S M Yu; Z J Cheng; J H Guh; F Y Lee; S C Kuo
Journal:  Biochem J       Date:  1995-03-15       Impact factor: 3.857

9.  Neurotransmitter receptors mediate cyclic GMP formation by involvement of arachidonic acid and lipoxygenase.

Authors:  R M Snider; M McKinney; C Forray; E Richelson
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

10.  YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.

Authors:  C C Wu; F N Ko; S C Kuo; F Y Lee; C M Teng
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.